{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:24:54Z","timestamp":1787228694955,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin-6 (IL-6) and ferritin are routinely monitored during chimeric antigen receptor T-cell (CAR-T) therapy; however, their temporal dynamics and outcome-specific relevance remain inadequately characterized. This study aimed to evaluate the value of IL-6 and ferritin at multiple time points in patients with diffuse large B-cell lymphoma (DLBCL) receiving anti-CD19 CAR-T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 54 patients (median age 49.0 years; 64.8% male) were retrospectively analyzed. Post-infusion IL-6 and ferritin levels were measured on day 1, day 7, day 14, and the peak value was defined as the highest level within the first 14 days after infusion. Survival was evaluated using Cox proportional hazards regression, while logistic regression was used for binary outcomes, with Firth penalized regression performed as a sensitivity analysis. Spearman correlation was used to characterize relationships between IL-6, ferritin, and routine laboratory parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CRS occurred in 68.5% of patients, and the objective response rate was 70.4%. IL-6 levels were significantly higher in patients with CRS at day 1 (\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.003) and at peak levels (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.005). IL-6 on day 7 was associated with mortality (OR\u00a0=\u00a01.625, 95% CI: 1.076-2.737,\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.038). Ferritin was associated with CRS at all time points and showed an exploratory association with mortality, but not with treatment response. Day 7 IL-6 showed the numerically highest AUC for death status, whereas Day 14 ferritin showed the numerically highest AUC for CRS. IL-6 was negatively correlated with albumin at Day +1, Day +7, and peak, whereas ferritin was negatively correlated with RBC count at Day +1, Day +7, and peak.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serial IL-6 and ferritin measurements were associated with CRS-related inflammatory status. Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1906304","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:28Z","timestamp":1787118388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of IL-6 and ferritin dynamics on clinical outcomes after anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Ling","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]},{"name":"Department of Hematology, Funing County People\u2019s Hospital of Jiangsu Province","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yancheng First People\u2019s Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First People\u2019s Hospital of Huai\u2019an","place":["Huai\u2019an, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Hematology, Bozhou People\u2019s Hospital","place":["Bozhou, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Shen","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]},{"name":"Cell Research and Translational Medicine Center, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]},{"name":"Blood Diseases Institute, Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00166-2","article-title":"Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes","volume":"9","author":"Kang","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1265835","article-title":"Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy","volume":"10","author":"Dou","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12129","article-title":"Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: a meta-analysis","volume":"25","author":"Cheng","year":"2025","journal-title":"Biomol BioMed"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.014","article-title":"High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma","volume":"59","author":"Dlouhy","year":"2017","journal-title":"Leuk Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156289","article-title":"Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes","volume":"169","author":"Bao","year":"2023","journal-title":"Cytokine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0056","article-title":"Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35316","article-title":"Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"130","author":"Wang","year":"2024","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31171","article-title":"Diagnostic pitfalls in assessment of ferritin following CAR-T-cell therapy: understanding the hook effect","volume":"71","author":"Harb","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation","volume":"29","author":"Kernan","year":"2017","journal-title":"Int Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102778","article-title":"Ferritin - from iron, through inflammation and autoimmunity, to COVID-19","volume":"126","author":"Mahroum","year":"2022","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15166","article-title":"Investigation and management of a raised serum ferritin","volume":"181","author":"Cullis","year":"2018","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)80476-4","article-title":"Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes","volume":"242","author":"Castell","year":"1989","journal-title":"FEBS Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq411","article-title":"Serum IL-6, albumin and comorbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis","volume":"26","author":"Hung","year":"2010","journal-title":"Nephrol Dialysis Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12662","DOI":"10.1038\/s41598-025-96533-2","article-title":"Study on ferritin and liver injury in pediatric hemophagocytic lymphohistiocytosis associated with infection","volume":"15","author":"Hao","year":"2025","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05606-7","article-title":"A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin\/platelet ratio","volume":"103","author":"Feng","year":"2024","journal-title":"Ann Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14185","article-title":"Value of hemophagocytosis in the diagnosis of hemophagocytic lymphohistiocytosis in critically ill patients","volume":"112","author":"Nyvlt","year":"2024","journal-title":"Eur J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13489","article-title":"Increasing ferritin predicts early death in adult hemophagocytic lymphohistiocytosis","volume":"43","author":"Abou Shaar","year":"2021","journal-title":"Int J Labor Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:35:18Z","timestamp":1787225718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1906304"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1906304","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1906304"}}